Mucopolysaccharidosis type 1 (MPS IH, Hurler syndrome) is a rare genetic disorder caused by deficiency of enzyme α-Liduronidase, which is needed for degradation of glycosaminoglycans (GAG) 
Introduction
Mucopolysaccharidoses are a group of rare genetic disorders caused by the deficiency of lysosomal enzymes that catabolize glycosaminoglycans.
All the mucopolysaccharidoses are inherited in an autosomal recessive pattern except Hunter disease (X-linked) (2) . Hurler syndrome occurs due to mutation in the IDUA gene mapped to the chromosome 4p16.3 encoding for α-Liduronidase (1). It is the most common and severe form of mucopolysaccharidoses. The incidence of MPS IH has been reported to be 1:1,00,000 per childbirth. MPS I has wide phenotypic variation, partly determined by residual enzyme level and the mutant allele.
Case Report
An 8-year-old male child born out of third-degree consanguineous marriage, first in birth order, was brought to pediatrics department with the chief complaint of seizures of 2days duration and intellectual disability with associated skeletal deformities observed since early childhood http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v8i2.22 (approximately 1year of age). There was no significant perinatal history, and the younger sibling was healthy. The child had low intelligence quotient with speech disability and mild hearing loss. On examination (Fig 1) child had coarse facial features with a large head, prominent forehead, flat nasal bridge, broad nasal tip, large tongue, and short stature, multiple skeletal deformities with joint contractures, mild corneal clouding, hepatomegaly, splenomegaly. Echocardiogram showed mild mitral regurgitation with the thickened mitral valve. MRI brain revealed mild hydrocephalus. Because of specific clinical and radiological features, mucopolysaccharidosis type 1 was suspected, and for confirmation of diagnosis, enzyme assay was sent, which showed low levels of α-Liduronidase, i.e.,1.05 nmol/hr/ml (normal range was 2.4-12nmol/hr/ml). Urinary excretion of glycosaminoglycans was not done. The child was stabilized and started on anti-epileptics for control of seizures. The child developed pneumonia during the hospital stay and was treated. Later, Child was sent to a higher center for further genetic analysis and enzyme replacement therapy.
Discussion
Hurler disease is a severe, progressive disorder with multiple organ and tissue involvement that results in premature death usually within 1st decade if left untreated as a result of cardio respiratory failure and progressive neurological disease (3) . Children with Hurler syndrome are normal at birth except for inguinal hernia and are usually diagnosed between 6 months to 24 months of age (1) . They have a variable degree of growth failure, intellectual disability, coarse facial features, joint contractures, organomegaly, corneal clouding, dysostosis multiplex, glycosaminoglycanuria (2) . Children with hurler syndrome also have a loss of vision (due to pigmentary retinopathy), hearing loss, otitis media, obstructive sleep apnea, recurrent respiratory infections. Cardiac involvement results in regurgitation across valves, cardiomyopathy, arrhythmias, and requires cardiac evaluation every 1 or 2 years after initial diagnosis (3) . Regular dental and radiological assessment should be performed every six months and parents or caregivers should be educated about dental home care (4, 5) . Hydrocephalus and spinal cord compression can also occur. Children with MPS I Hurler-Scheie have a later age at onset, usually in the second half of 1st decade and second decade or beyond for MPS I Scheie.
Children with Scheie disease have preserved intellectual functioning (2) . Early diagnosis and intervention can improve the life expectancy and quality of life in these children. A multidisciplinary approach is most crucial in the management of these patients and includes regular assessments, supportive care, and treatment of a variety of systemic complications (6, 7) . Hematopoietic stem cell therapy (HSCT) and enzyme replacement therapy (ERT) are currently available definitive treatment options along with providing supportive care (8) . HSCT if done early (<2 yrs), can halt the progression of disease & improves life expectancy, quality of life, growth, respiratory symptoms, visceromegaly, joint mobility, hearing, vision (10) . Enzyme activity in serum and urinary GAG excretion normalizes. HSCT does not significantly improve the neuropsychological outcome in patients with impaired cognition at the time of presentation (1) . ERT using recombinant α-L-iduronidase (Aldurazyme) has been approved in MPS-I. The enzyme does not cross the blood-brain barrier & does not prevent deterioration of cognition and other neurological functions. It is often instituted before stem cell transplant, and both may be combined for a better outcome (9) . Newer approaches such as intrathecal ERT, ERT with fusion proteins to cross the BBB, gene therapy, substrate reduction therapy (SRT), chaperone therapy, and some combination of these strategies may provide better outcome for MPS patients in the near future (11) . Primary prevention through genetic counseling and tertiary prevention to avoid or arrest complications remain the mainstay of pediatric care. Newborn screening methods by tandem mass spectrometry are available recently for early diagnosis of the disease so that treatment can be initiated early (12) . 
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